EFFICACY, SAFETY AND COMPLIANCE OF TERAZOSIN IN THE TREATMENT OF PATIENTS WITH SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA.
AbstractBackground: The primary objective of this study was to determine the efficacy, safety and compliance of terazosin, aselective long-acting alpha 1-blocker, for the treatment of symptomatic BPH. Methods: A total of 150 patients rangingin age between 45 and 81 years with symptomatic BPH were included. They were randomly assigned to receiveterazosin (n =74) or placebo (n = 76) for 12 weeks. Results: Terazosin significantly improved urinary symptoms versusplacebo, assessed by using the 1-PSS (-30vs. -17%, P=0.007). Maximum flow rate increased significantly withterazosin (2.3 ml/s i.e. ± 28%) compared with placebo (1.1 ml/s i.e. ±13%, P=0.006). Residual urine was alsosignificantly reduced with terazosin. Overall, terazosin was as well tolerated as placebo. Seven patients werewithdrawn from the study for adverse events with terazosin (9.45%) and eight patients (10.52%) with placebo. Theincidence of vasodilatation-related events like postural symptoms, dizziness, headache with terazosin was similar(8.11%) to that of placebo (7.90%). The reduction in supine blood pressure was minor (< 5mm Hg), both innormotensive and hypertensive patients. Conclusion: This study demonstrates the efficacy, safety and compliance ofterazosin for the treatment of BPH.
Berry, S.J., Coffery, D. S., Walsh, P.C. and Ewing,
L; The development of human benign prostatic
hypertrophy with age. J. Urol., 1984;132:474-
Rutkow. I.M.: Urological operations in the United
States, 1979-1984. J. Urol., 1986; 13 5:1206
Turner-war wick, R., Whiteaide, C.G., Arnold,
E.T.et al.: A Urodynamic view of prostatic
obstruction and results of prostatectomy. Br. J.
Ball, A.J.; Feneley, R.C. L and Abrams, P.H.: The
natural history of untreated “prostatism”.
Cockett, A. T.K., Aso, Y., Denis, L.et.al.:
Recommendations of the International Consensus
Committee Concerning: 4.BPH treatment
recommendations. Im Cocktt, A.T.K. et. al.
Editors. The 2nd International Consultations on
Benigin Prostatic Hyperplasia(BPH), Paris,
Caine, M: Alpha-adrenergic blockers for the
treatment of benign prostatic hyperplasia. Urol.
Lepor, H., Shapiro, E., Gup, D.I. et. al.:
Laboratory assessment of terazosin and alpha 1
blockade in prostatic hyperplasia. Urology,
Lepor, H.: Pharmacologic management of benign
prostatic hyperplasia. In:1992: Urology Annual.
Edited by Rous, S.N., Norwalk, 1991,PP. 1 -19.
Caine, M., Pfau, A. and Perlbery.S.: The use of
alpha- adrenergic blockers in benign prostatic
Hedlund, H. and Andersen, K.E., Ek. A.: Effects
of prazosin in patients with benign. prostatic
obstruction. J.Urol.,1983; 130:275.
Lacorow, J.W. and Dunn, M.: Indoramin: An
effective new drug in the management of bladder
outflow obstruction.Br.J.Urol.,1987; 60:526.
Ramsay, J.W. A., Scott, G. l. and Whitfield, H. N.:
A double-blind controlled trial of a new alpha 1
blocking drug in the treatment of bladder outflow
obstruction. Br. J. Urol., 1985;57:657.
Caine, M., Mazouz, B. and Rossini, B.M.: The
effect of nicergoline on the lower urinary tract
muscle. Urol.Res., 1984; 12:287.
Anderson, K. E., Hedlund, H., Larsson, B et. al.:
Ketanserine interaction with urethral alphaadrenoreceptors. J. Urol., 1987. 37:534.
JAMC, Vol. 12, No. 2, 2000
Lepor. H., Baumann, M. and Shapiro, E.: The
alpha-adrenergic binding properties of terazosin
in the human prostate adenoma and caine brain.
Dunzendrofer, U.: Clinical experience.
Symptomatic management of BPH with terazosin
therapy. Urology. 1988;32 (Suppl.): 27.
Lipsitz, L. A.: orthostatic hyperplasia in the
elderly. New Engl.J.med.,1989;321:952.
Chappie, C.R., Carter, P., Christmas, T. J. et. al.:
A three-month double blind study of doxazosin as
treatment of benign prostatic bladder outlet
Lepor, H., Meretyk, S. and Knapp-.Maloney. G:
The safety, efficacy and compliance of terazosin
thrapy for benign prostatic hyperplasia. J. Urol.,
Lepor, H., Auerbach, S., Puras-Baez, A. et. al.: A
randomized, placebo controlled multicenter study
of the efficacy and safety of terazosin in the
treatment of benign prostatic hyperplasia. J.
Urol., 1992; 148:1467-1474.
Journal of Ayub Medical College, Abbottabad is an OPEN ACCESS JOURNAL which means that all content is FREELY available without charge to all users whether registered with the journal or not. The work published by J Ayub Med Coll Abbottabad is licensed and distributed under the creative commons License CC BY ND Attribution-NoDerivs. Material printed in this journal is OPEN to access, and are FREE for use in academic and research work with proper citation. J Ayub Med Coll Abbottabad accepts only original material for publication with the understanding that except for abstracts, no part of the data has been published or will be submitted for publication elsewhere before appearing in J Ayub Med Coll Abbottabad. The Editorial Board of J Ayub Med Coll Abbottabad makes every effort to ensure the accuracy and authenticity of material printed in J Ayub Med Coll Abbottabad. However, conclusions and statements expressed are views of the authors and do not reflect the opinion/policy of J Ayub Med Coll Abbottabad or the Editorial Board.
USERS are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author. This is in accordance with the BOAI definition of open access.
AUTHORS retain the rights of free downloading/unlimited e-print of full text and sharing/disseminating the article without any restriction, by any means including twitter, scholarly collaboration networks such as ResearchGate, Academia.eu, and social media sites such as Twitter, LinkedIn, Google Scholar and any other professional or academic networking site.